vs
Apellis Pharmaceuticals, Inc.（APLS）与OMNICELL, INC.（OMCL）财务数据对比。点击上方公司名可切换其他公司
OMNICELL, INC.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$309.9M vs $199.9M），OMNICELL, INC.净利率更高（3.7% vs -29.5%，领先33.2%），OMNICELL, INC.同比增速更快（14.9% vs -5.9%），OMNICELL, INC.自由现金流更多（$38.6M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 5.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Omnicell是总部位于美国加州山景城的跨国医疗科技企业，专注于为医院及各类医疗机构提供药品管理自动化系统，同时面向零售药房推出用药依从性包装与患者互动软件，旗下产品使用Omnicell及EnlivenHealth两大品牌。
APLS vs OMCL — 直观对比
营收规模更大
OMCL
是对方的1.6倍
$199.9M
营收增速更快
OMCL
高出20.8%
-5.9%
净利率更高
OMCL
高出33.2%
-29.5%
自由现金流更多
OMCL
多$52.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
5.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $309.9M |
| 净利润 | $-59.0M | $11.4M |
| 毛利率 | — | 45.3% |
| 营业利润率 | -25.6% | 60.1% |
| 净利率 | -29.5% | 3.7% |
| 营收同比 | -5.9% | 14.9% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSOMCL
| Q1 26 | — | $309.9M | ||
| Q4 25 | $199.9M | $314.0M | ||
| Q3 25 | $458.6M | $310.6M | ||
| Q2 25 | $178.5M | $290.6M | ||
| Q1 25 | $166.8M | $269.7M | ||
| Q4 24 | $212.5M | $306.9M | ||
| Q3 24 | $196.8M | $282.4M | ||
| Q2 24 | $199.7M | $276.8M |
净利润APLSOMCL
| Q1 26 | — | $11.4M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $5.5M | ||
| Q2 25 | $-42.2M | $5.6M | ||
| Q1 25 | $-92.2M | $-7.0M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $8.6M | ||
| Q2 24 | $-37.7M | $3.7M |
毛利率APLSOMCL
| Q1 26 | — | 45.3% | ||
| Q4 25 | — | 41.5% | ||
| Q3 25 | — | 43.3% | ||
| Q2 25 | — | 43.9% | ||
| Q1 25 | — | 41.1% | ||
| Q4 24 | — | 46.2% | ||
| Q3 24 | — | 43.3% | ||
| Q2 24 | — | 41.3% |
营业利润率APLSOMCL
| Q1 26 | — | 60.1% | ||
| Q4 25 | -25.6% | 0.1% | ||
| Q3 25 | 48.7% | 2.7% | ||
| Q2 25 | -18.6% | 2.8% | ||
| Q1 25 | -50.0% | -4.3% | ||
| Q4 24 | -12.3% | 4.0% | ||
| Q3 24 | -24.0% | 2.3% | ||
| Q2 24 | -14.7% | 1.2% |
净利率APLSOMCL
| Q1 26 | — | 3.7% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 1.8% | ||
| Q2 25 | -23.6% | 1.9% | ||
| Q1 25 | -55.3% | -2.6% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 3.1% | ||
| Q2 24 | -18.9% | 1.3% |
每股收益（稀释后）APLSOMCL
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.40 | $-0.05 | ||
| Q3 25 | $1.67 | $0.12 | ||
| Q2 25 | $-0.33 | $0.12 | ||
| Q1 25 | $-0.74 | $-0.15 | ||
| Q4 24 | $-0.30 | $0.34 | ||
| Q3 24 | $-0.46 | $0.19 | ||
| Q2 24 | $-0.30 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $239.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.3B |
| 总资产 | $1.1B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSOMCL
| Q1 26 | — | $239.2M | ||
| Q4 25 | $466.2M | $196.5M | ||
| Q3 25 | $479.2M | $180.1M | ||
| Q2 25 | $370.0M | $399.0M | ||
| Q1 25 | $358.4M | $386.8M | ||
| Q4 24 | $411.3M | $369.2M | ||
| Q3 24 | $396.9M | $570.6M | ||
| Q2 24 | $360.1M | $556.8M |
股东权益APLSOMCL
| Q1 26 | — | $1.3B | ||
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.3B | ||
| Q1 25 | $164.2M | $1.3B | ||
| Q4 24 | $228.5M | $1.2B | ||
| Q3 24 | $237.1M | $1.2B | ||
| Q2 24 | $264.3M | $1.2B |
总资产APLSOMCL
| Q1 26 | — | $2.0B | ||
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.1B | $1.9B | ||
| Q2 25 | $821.4M | $2.1B | ||
| Q1 25 | $807.3M | $2.2B | ||
| Q4 24 | $885.1M | $2.1B | ||
| Q3 24 | $901.9M | $2.3B | ||
| Q2 24 | $904.5M | $2.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $54.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $38.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 12.5% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 4.80× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $110.8M |
8季度趋势，按日历期对齐
经营现金流APLSOMCL
| Q1 26 | — | $54.5M | ||
| Q4 25 | $-14.2M | $30.4M | ||
| Q3 25 | $108.5M | $28.3M | ||
| Q2 25 | $4.4M | $42.8M | ||
| Q1 25 | $-53.4M | $25.9M | ||
| Q4 24 | $19.4M | $56.3M | ||
| Q3 24 | $34.1M | $22.8M | ||
| Q2 24 | $-8.3M | $58.7M |
自由现金流APLSOMCL
| Q1 26 | — | $38.6M | ||
| Q4 25 | $-14.3M | $22.6M | ||
| Q3 25 | $108.3M | $18.5M | ||
| Q2 25 | $4.4M | $31.0M | ||
| Q1 25 | $-53.4M | $14.8M | ||
| Q4 24 | $19.3M | $47.2M | ||
| Q3 24 | — | $13.9M | ||
| Q2 24 | $-8.4M | $49.1M |
自由现金流率APLSOMCL
| Q1 26 | — | 12.5% | ||
| Q4 25 | -7.1% | 7.2% | ||
| Q3 25 | 23.6% | 6.0% | ||
| Q2 25 | 2.5% | 10.7% | ||
| Q1 25 | -32.0% | 5.5% | ||
| Q4 24 | 9.1% | 15.4% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | -4.2% | 17.8% |
资本支出强度APLSOMCL
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.5% | ||
| Q3 25 | 0.0% | 3.1% | ||
| Q2 25 | 0.0% | 4.1% | ||
| Q1 25 | 0.0% | 4.1% | ||
| Q4 24 | 0.0% | 3.0% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 3.5% |
现金转化率APLSOMCL
| Q1 26 | — | 4.80× | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 5.18× | ||
| Q2 25 | — | 7.58× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | 15.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
OMCL
| Product revenues | $174.8M | 56% |
| Service revenues | $135.1M | 44% |
